Description

Simple

Clinical

Overview

Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Pharmacodynamic

Information currently not available.

Mechanism of action

Vintafolide minimizes the off-target toxicity by delivering the vinca molecule directly and specifically to cancer cells that over-express the folate-receptor. Once delivered to the cancer cell surface, Vintafolide is internalized into the cancer cell via endocytosis, a natural cellular process. On... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vintafolide
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
6-Deoxyerythronolide B
The serum concentration of Vintafolide can be increased when it is combined with 6-Deoxyerythronolide B.
Ancestim
The risk or severity of peripheral neuropathy can be increased when Ancestim is combined with Vintafolide.
AVE9633
The serum concentration of Vintafolide can be increased when it is combined with AVE9633.
Balugrastim
The risk or severity of peripheral neuropathy can be increased when Balugrastim is combined with Vintafolide.
Brefeldin A
The serum concentration of Vintafolide can be increased when it is combined with Brefeldin A.
Bryostatin 1
The serum concentration of Vintafolide can be increased when it is combined with Bryostatin 1.
Candicidin
The serum concentration of Vintafolide can be increased when it is combined with Candicidin.
Carbomycin
The serum concentration of Vintafolide can be increased when it is combined with Carbomycin.
Cethromycin
The serum concentration of Vintafolide can be increased when it is combined with Cethromycin.
Clarithromycin
The serum concentration of Vintafolide can be increased when it is combined with Clarithromycin.
Coltuximab ravtansine
The serum concentration of Vintafolide can be increased when it is combined with Coltuximab ravtansine.
Darbepoetin alfa
The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vintafolide.
Dirithromycin
The serum concentration of Vintafolide can be increased when it is combined with Dirithromycin.
Doramectin
The serum concentration of Vintafolide can be increased when it is combined with Doramectin.
Epoetin delta
The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vintafolide.
Epofolate
The serum concentration of Vintafolide can be increased when it is combined with Epofolate.
Epothilone D
The serum concentration of Vintafolide can be increased when it is combined with Epothilone D.
Eprinomectin
The serum concentration of Vintafolide can be increased when it is combined with Eprinomectin.
Erythromycin
The serum concentration of Vintafolide can be increased when it is combined with Erythromycin.
Erythropoietin
The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vintafolide.
2 References
  1. 1 . Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, Vetzel M: Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer. 2007 Oct 1;121(7):1585-92.PubMed: 17551919
  2. 2 . Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP: Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007 May 1;67(9):4434-42.PubMed: 17483358